Patient Demographics and Characteristics
Characteristic | Details | Total | CR | LR | DR |
Mean age (y) | 58 (39–77) | 59 (39–77) | 58 (46–74) | 59 (40–76) | |
Sex | Male | 31 (79) | 7 (64) | 15 (88) | 9 (81) |
Female | 8 (21) | 4 (36) | 2 (12) | 2 (18) | |
Histology | SCC | 21 (54) | 2 (18) | 14 (82) | 5 (45) |
ADC | 10 (26) | 5 (45) | 1 (6) | 4 (36) | |
LCUC | 8 (20) | 4 (36) | 2 (12) | 2 (18) | |
TNM stage | IIa | 3 (8) | 1 (9) | 11 (6) | 1 (9) |
IIb | 2 (5) | 1 (9) | 1 (6) | 0 | |
IIIa | 15 (38) | 4 (36) | 8 (47) | 3 (27) | |
IIIb | 19 (49) | 5 (45) | 7 (41) | 7 (64) | |
Location of tumor | RSL | 19 (39) | 5 (45) | 6 (35) | 8 (73) |
RML | 3 (8) | 1 (9) | 2 (12) | 0 | |
RIL | 3 (8) | 2 (18) | 1 (6) | 0 | |
LSL | 11 (28) | 3 (27) | 6 (35) | 2 (18) | |
LIL | 4 (10) | 0 | 3 (18) | 1 (9) | |
Induction chemotherapy | Yes | 33 (85) | 9 (81) | 13 (76) | 10 (91) |
No | 6 (15) | 2 (18) | 4 (24) | 1 (9) | |
Dose (Gy) | At PETC | 44 (40–52) | 45 (42–50) | 45 (40–52) | 43 (40–46) |
Total | 67 (60–70) | 66 (60–70) | 67 (60–70) | 68 (66–70) | |
Time of follow-up (mo) | 30 (6–76) | 46 (18–76) | 22 (6–60) | 27 (11–51) | |
RT duration (d) | 48 (39–66) | 47 (41–53) | 48 (39–66) | 48 (45–52) | |
SUVmax | PETA | 11.0 (3.7–22.1) | 11.7 (5.5–18.1) | 11.7 (3.7–22.1) | 10.9 (5.1–16.6) |
PETB | 8.4 (1.2–20.8) | 7.5 (1.2–15.2) | 9.1 (2.5–18.9) | 8.4 (2.8–20.8) | |
PETC | 5.6 (0.8–13.1) | 4 (0.8–5.9) | 6.8 (2.3–11.9) | 5.2 (1.1–3.15) | |
MTV (cm3) | PETA (A40) | 54.0 (2.4–176.3) | 44.8 (6.6–125.8) | 63.8 (10.6–176.3) | 47.0 (2.4–103.2) |
PETB (B40) | 26.2 (1.7–86.6) | 18.2 (0.7–31.2) | 32.4 (9.2–86.6) | 24.8 (1.5–73.4) | |
PETC (C40) | 30.9 (0.8–77.8) | 28.6 (0.8–77.6) | 34 (4.2–76.2) | 5.2 (2.9–57.8) |
SCC = squamous cell carcinoma; ADC = adenocarcinoma; LCUC = large cell undifferentiated carcinoma; RSL = right superior lobe; RML = right median lobe; RIL = right inferior lobe; LSL = left superior lobe; LIL: = left inferior lobe; RT = radiotherapy; MTV = metabolic tumor volume.
Data in parentheses are percentages or ranges.